Endpoints Unveils 2022 List of Most Promising Biotech Startups

Well-known industry media Endpoints released the "Most Promising Biotech Startups of 2022" list, featuring 11 biotechnology companies.These cutting-edge research fields include cell therapy, gene editing,Circular RNA,Artificial Intelligence（AI）etc., they are targetingTumors, Asthma, Brain Diseases, Autoimmune Diseases, Cardiometabolic DiseasesDeveloping Innovative Therapies for Diseases。This article will introduce these 11 rising stars to readers by combining this list with official information from each company.

Affini-T Therapeutics

Focus Area: Solid Tumor Cell Therapy

Affini-T Therapeutics is dedicated to developing potentially life-changing drugs for patients with refractory solid tumors, and its proprietary platform may provide new opportunities for those carrying...KRASPatients with mutations (one of the most common oncogenic driver mutations in solid tumors) are provided with transformative therapies. Affini-T Therapeutics' proprietary platform is designed to select and engineer the right immune cells to generate durable and coordinated immune responses. The company’s innovative synthetic biology switchesCan rewrite the rules of the tumor microenvironment by enhancing T-cell persistence, establishing sustained responses, and improving T-cell functionality through enhanced tumor infiltration.。

In March 2022, Affini-T Therapeutics announced the completion of a $175 million financing round.To drive the operation of its drug discovery engine platform and seek to advance multiple targeted oncogene research and development projects into clinical stages. Currently, the company's R&D pipeline includes targetingKRAS G12VAndKRAS G12DMutant, andp53Candidate TCR Cell Therapy for Mutants. Investigational therapies targeting virus-driven cancers have entered clinical development.

Altos Labs

Focus Area: Cell Programming

Altos LabsIn 2022Announced official launch in January and secured $3 billion in financing.The companyAimed at discovering the secret of cellular rejuvenation, reshaping cellular health, and enabling resistance to diseases.According to Dr. Klausner, the founder of Altos Labs, in an earlier interview, Altos Labs is a company that reverses diseases by developing drugs. By programming cells in various ways, these cells can be made to have optimized resistance. This resistance refers to withstanding stress, promoting repair, or regeneration.

Public information shows that Altos LabsA biotechnology company that has attracted four Nobel laureates and many top scientists from around the world.Scientist TeamIncluding Professor Peter Walter, a pioneer in the unfolded protein response in cells, Professor Juan Carlos Izpisua Belmonte, a renowned scientist in the field of regenerative medicine, and Professor Wolf Reik, an expert in epigenetic reprogramming and cellular senescence in mammalian cells, among others.Board MembersIncludes the 2018 Nobel Prize in Chemistry laureateProfessor Frances Arnold、2020 Nobel Prize in Chemistry LaureateProfessor Jennifer Doudna、And Professor David Baltimore, the 1975 Nobel Prize winner in Physiology or Medicine.

Areteia Therapeutics

Focus Area: Small Molecule Drugs for Asthma Treatment

Areteia Therapeutics is a clinical-stage small molecule drug development company dedicated to providing better treatment options for asthma patients and improving their quality of life. It is reported that the lead candidate drug in the company’s pipelineDexpramipexole is an orally administered small-molecule drug that treats eosinophilic asthma by inhibiting the maturation and release of eosinophils in the bone marrow.Phase 2 clinical results for patients with severe eosinophilic asthma showed that the candidate drugWell tolerated after administrationThe number of eosinophils in the patient's blood was significantly reduced.

In July 2022, Areteia Therapeutics secured $350 million in Series A funding., to advance the research and development of small-molecule drugs for asthma treatment.

Generate Biomedicines

Focus Area: Leveraging AI to Develop Customized Protein Therapies

Generate Biomedicines was founded by the renowned healthcare investment firm Flagship Pioneering. The company’s machine learning system discovers statistical patterns linking amino acid sequences to protein structure and function by analyzing hundreds of millions of known proteins. Based on these statistical patterns, the machine learning system can generate customized protein therapeutics, ranging from simple peptides to complex antibodies, proteases, or other protein-based therapies.This technology allows drug developers to create protein drugs targeting specific targets without relying on trial-and-error high-throughput screening.

January 2022, Generate Biomedicines, Inc.Entered into a R&D collaboration with Amgen worth up to $1.9 billionThe two parties will utilize the artificial intelligence drug discovery technology platform developed by the former to develop protein therapies for 5 clinical targets, involving multiple therapeutic areas and treatment modalities. Additionally, Generate Biomedicines was featured in 2022.Forbes AI 50 Emerging StarsList。

Mammoth Biosciences

Focus Area: CRISPR Gene Editing

Mammoth Biosciences is a CRISPR gene-editing technology development company established in 2017. One of its co-founders, Dr. Jennifer Doudna, is a recipient of the 2020 Nobel Prize in Chemistry.Dedicated to leveraging CRISPR gene editing technology to develop potential "best-in-class" in vivo and ex vivo gene therapies, providing permanent cures for difficult-to-treat diseases.Its proprietary CRISPR platform can discover and engineer novel Cas enzymes. These enzymes possess several characteristics, such as ultra-small size, enhanced thermal stability, faster reaction kinetics, high fidelity, and excellent targeting capability, which are expected to help develop CRISPR-based treatments and diagnostic methods for a variety of diseases.

In September 2021, Mammoth Biosciences completed nearly $200 million in financing., will develop a variety of CRISPR-based therapies and diagnostic methods using novel Cas enzymes. In January 2022, the companyAnnounced a collaboration with Bayer worth over $1 billion, aiming to organically combine the former's CRISPR system with the latter's induced pluripotent stem cell (iPSC) platform to develop the next generation of in vivo gene editing therapies for the treatment of liver diseases.

Metagenomi

Focus Area: Gene Editing Therapy

Metagenomi is a next-generation gene editing therapy research and development company,Dedicated to leveraging a toolbox of next-generation gene editing systems to develop potential therapeutic drugs.The core strategy of the company's gene editing discovery and development system is to start with a vast amount of metagenomic data, utilize advanced AI-based cloud computing to discover natural nucleases from nature, and then engineer them to create gene editing therapies. To date, Metagenomi has tested hundreds of new gene editing tools and validated their utility in human therapeutics.

In January 2022, Metagenomi announced the completion of a $175 million Series B financing round., bringing the company's total financing to $300 million. The funds from this round will be used to advance the company’s leading in vivo and in vitro gene editing projects into clinical trials. Previously, the company had alsoStrategic R&D Collaboration with Moderna, focusing on advancing the therapeutic applications of new gene editing systems in the human body.

Neumora Therapeutics

Focus AreaField: Brain Diseases

Neumora Therapeutics announced its emergence from stealth mode in October 2021.Will integrate data science and neuroscience to develop precision therapies for brain diseases, including depression and Alzheimer's disease.At the same time, the company also obtainedAmgen$100 million equity investment, and a collaborative development project targeting casein kinase 1δ and glucocerebrosidase. Neumora's proprietary neural network technology will integrate genomics, imaging, electroencephalography, and clinical data to uncover the underlying mechanisms of brain diseases and map out specific patient subtypes.

According to the Neumora company website, its R&D pipeline includes 7 ongoing projects.Among them, MNRA-140, used for treating depression, has entered Phase 2 clinical trials. The unique feature of this drug is its ability to address the symptom where depression patients are unable to feel pleasure. The company will utilize a screening technology to generate a digital biomarker based on patients' responses in questionnaires, identifying those most suitable for this therapy.

Odyssey Therapeutics

Focus Areas:Cancer and Inflammatory Diseases

Odyssey Therapeutics, founded in 2018, is aA biotechnology company developing a new generation of immunomodulators and oncology drugs, focusing on targets and mechanisms that control key signaling nodes driving diseases., providing patients with drugs that have better product characteristics. The company is applying its highly integrated integrated drug discovery engine, along with advanced AI computing and data science platforms, to high-potential targets that are difficult to drug using traditional drug discovery methods. These targets have the potential to completely transform the current therapeutic paradigm and will bring new therapies to patients with few treatment options for certain diseases.

In December 2021, Odyssey Therapeutics announced the completion of a $218 million Series A financing round.To advance multiple pipeline programs and further expand its drug discovery platform, extending the targetable druggable genome in the fields of oncology and immunology.

Focus Area: Drug Development Using Targeted Repetitive Genome Technology

ROME Therapeutics was founded in 2020 with the goal ofTargeting non-coding genes known as the repeatome, developing innovative therapies for cancer and autoimmune diseases. Repetitive genomic elements are usually in a "dormant" state; however, when cells are under stress, they can be activated, potentially triggering the innate immune system to eliminate damaged cells. ROME Therapeutics' strategy isBy activating or inhibiting specific repetitive genomes, the innate immune system can be activated or suppressed to treat various disease types such as cancer, infections, and autoimmune diseases.。

September 2021,ROME TherapeuticsAnnounced the completion of a $77 million Series B financing round, thereby developing new therapies targeting repetitive genomic elements in non-coding genes for the treatment of cancer and autoimmune diseases. Currently, the company has established a repetomics platform and identified multiple targets applicable to drug discovery.

Versanis Bio

Focus Areas:Cardiometabolic Diseases

Versanis Bio was founded in 2021.Advancing the Development of New Therapies for Cardiometabolic Diseases。The companyThe main project, bimagrumab, was introduced from Novartis.A Fully Human Monoclonal Antibody Targeting Activin Receptor Type II, which can block the binding of ligands such as activin A and myostatin. Previously, this product has demonstrated sustained and effective induction of significant fat mass reduction without reducing lean mass (muscle mass) in pivotal studies. Additionally, it improved glycated hemoglobin (HbA1c) and other cardiometabolic parameters.

In August 2021, Versanis Bio announced the completion of a $70 million Series A financing round., to advance the clinical development of bimagrumab. The company is currently conducting a Phase 2b study for the treatment of obesity to evaluate the product's potential to help obese patients reduce fat and improve body composition.。